Score Overview
Explore the 2021 public Archive ranking →
Where Elicio Therapeutics Inc. has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ELTX does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-23 | $ 1.90 | — |
1 Year2025-10-23 | $ 9.50 | -80.00% |
5 Years2021-10-22 | $ 85.70 | -97.78% |
All Time2021-02-05 | $ 170.20 | -98.88% |
| Period | Last Price2026-10-23 | 1 Year2025-10-23 | 5 Years2021-10-22 | All Time2021-02-05 |
|---|---|---|---|---|
| Price | $ 1.90 | $ 9.50 | $ 85.70 | $ 170.20 |
| Return | — | -80.00% | -97.78% | -98.88% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 0.00 | -$ 37M | $ 23M |
| 2025 | $ 0.00 | -$ 39M | $ 18M |
| 2024 | $ 0.00 | -$ 51M | $ 17M |
| 2023 | $ 0.00 | -$ 35M | $ 12M |
| 2022 | $ 0.00 | -$ 28M | $ 7M |
| IPO2021 | $ 28M | -$ 26M | $ 88M |
Elicio Therapeutics Inc. fundamental performance
Between 2021 and 2025, revenue declined from $ 28M to $ 0.00 and net income went from -$ 26M to -$ 39M. Revenue increased in 0% of the years measured; net income in 40%.
Elicio Therapeutics Inc. currently holds a 5-year HDB Score of 2.5 out of 10. How the HDB Score is calculated.
Membership
Explore ELTX with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,112 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
Explore other companies
Collplant Biotechnologies LtdCLGN· revenue grew in 40% of years
Cartesian Therapeutics Inc.RNAC· revenue grew in 40% of years
WW International, Inc. Common StockWW· revenue grew in 0% of years
Crispr Therapeutics AGCRSP· revenue grew in 33% of years
Candel Therapeutics IncCADL· revenue grew in 0% of years
